TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2.~* Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor~* Patient meets at least 1 of the following criteria:~  * Disease progression despite standard therapies~ * No standard therapies are available or such therapies are not anticipated to result in a durable response~ * Standard therapies are considered unsuitable or have been refused~* Life expectancy \> 12 weeks~* Able to be hospitalized from 1 day prior to the initial dosing until day 15 of the dosing, and from day 27 until day 29 of the dosing~Exclusion Criteria:~* Patient exhibits persistent subjective and objective findings of toxicity ≥ Grade 2 (CTCAE v4.0-JCOG) from the previous cancer treatment with antitumor effect (except of alopecias)~* Received previous treatment with antitumor effect within 21 days prior to the scheduled initial dosing~* Patient had a major surgical procedure within 21 days prior to the scheduled initial dosing or a major surgical procedure scheduled during the course of the study~* Use of an investigational drug or device within 21 days prior to the scheduled initial dosing~* Use of blood transfusion or hematopoietic growth factors within 14 days prior to the scheduled initial dosing~* A positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)~* Known history of a positive test for human immunodeficiency virus (HIV) infection~* Patient has central nervous system (CNS) or leptomeningeal involvement with clinical symptoms

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP3026 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing open colo-rectal surgery~Exclusion Criteria:~* ASA status more than II, history of chronic pain, ischemic heart disease or chronic pulmonary disease, allergy to any drugs used in the protocol. Body Max Index more than 35.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- zero/morphine (Type: NO_INTERVENTION): Patient received a standard balance anaesthesia and morphine for post operative pain.
- ketamine/morphine (Type: EXPERIMENTAL): Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery.
- zero/metadone (Type: EXPERIMENTAL): Methadone PCA
- ketamine/methadone (Type: EXPERIMENTAL): Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery.~Methadone administered by a PCA system (dose 2 mg, lock-out 12min.).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of FORTEO Use in Subjects in the Community Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women who are judged by the study physician to be suitable for FORTEO therapy. The FORTEO product labeling specifies those individuals diagnosed with osteoporosis who are considered to be at high risk for fracture~Exclusion Criteria:~* Subjects who have an increased baseline risk for osteosarcoma. These include Paget's disease of bone, pediatric populations and young adult patients with open epiphyses, prior external beam or implant radiation therapy involving the skeleton~* Subjects who have administered FORTEO or PTH therapy for more than two weeks directly before study entry~* Subjects who have completed a course of FORTEO or PTH therapy of at least 18 months duration before study entry

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FORTEO (teriparatide)-treated (Type: None): FORTEO-treated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has Type 1 or Type 2 diabetes mellitus~* has a history of chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for a duration of at least six months but less than or equal to five years prior to Screening~Exclusion Criteria:~* has neuropathy secondary to non-diabetic causes~* has a significant neurological disorder or a condition that can cause symptoms that mimic peripheral neuropathy or might confound assessment of PDN~* has other chronic pain with intensity at or greater than the bilateral pain in the feet/toes~* is using an implanted medical device (eg, spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for the treatment of pain~* is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Gel (Type: PLACEBO_COMPARATOR): Placebo Gel is vehicle without clonidine
- Clonidine Topical Gel (ARC-4558) (Type: ACTIVE_COMPARATOR): Clonidine Topical Gel contains 0.1% clonidine hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of 0.1% and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Phacoemulsification Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale~Exclusion Criteria:~1. Diagnosis or evidence of dry-eye-disease (DED)~2. IOP-lowering medications~3. Former incisional surgery~4. Former diagnosis of corneal disease~5. Diabetes~6. Autoimmune diseases~7. Mental diseases

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: ACTIVE_COMPARATOR): Sodium Hyaluronate 0.1% drops
- Control group (Type: ACTIVE_COMPARATOR): Sodium Hyaluronate 0.2% drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years old~2. Patients having PCI with stenting 24 hours prior randomization, meeting the following criteria :~   * Acute coronary syndrome (unstable angina or myocardial infarction)~  * TIMI risk score\>2~3. Platelet reactivity in PRU ≥235 24 hours post-PCI~4. Age≥75 years and/or weight\<60 Kg~4. Informed consent obtained in writing~Exclusion Criteria:~* A history of bleeding diathesis~* Chronic oral anticoagulation treatment~* Contraindications to antiplatelet therapy~* Known platelet function disorders~* PCI or coronary artery bypass surgery \< 3 months~* Unsuccessful PCI (residual stenosis \> 30% or flow \< Thrombolysis in myocardial infarction flow 3)~* Planned staged PCI in the next 30 days~* Hemodynamic instability~* hemodialysis~* Creatinine clearance \<25 ml/min~* inability to give informed consent~* High likelihood of being unavailable for the Day 30~* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.~* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding on longterm antiplatelet therapy.~* Any previous history of ischemic stroke, transient ischemic attack, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).~* Thrombocytopenia (\<100.000 / μL) at randomization~* Anaemia (Hct \<30%) at randomization~* Polycythaemia (Hct \> 52%) at randomization~* Periprocedural IIb/IIIa inhibitor administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 150mg per day for 15 days
- Prasugrel (Type: EXPERIMENTAL): Prasugrel 5mg for 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active hidradenitis in the stage I-III according to Hurleys classification. Patients are referred to a dermatology out-patient clinic or patients already in an established treatment program, where there is indication for new or different treatment, or surgical intervention. Patients must have typical affection of the disease of either axillae, groins, and/or perigenital/perianal area~Exclusion Criteria:~* Patients in need of emergency medical or surgical treatment of hidradenitis will be excluded until the disease is in a quiet, controlled phase.~Pregnant or lactating, as well as patients with neurological disease such as myasthenia gravis or motor neuron disease.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botulinum B Toxin (Type: EXPERIMENTAL): Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
- Placebo (Type: PLACEBO_COMPARATOR): Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (T2DM) treated with stable dose of metformin \> or = to 1500mg/day as monotherapy for at least 8 weeks~* Hemoglobin A1c (HbA1c) 7% to 10% at screening~* Body mass index (BMI) \< or = to 45 kg/m2~Exclusion Criteria:~* History of taking antihyperglycemic therapy other than metformin or metformin extended release (XR) during the 8 weeks prior to screening~* History of taking a dipeptidyl peptidase-4 (DPP-4) inhibitor or pramlintide during 12 weeks prior to screening~* History of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study~* History of prescription or over the counter weight loss medication during 3 months prior to screening~* Previous exposure to exenatide or any glucagon-like peptide-1 (GLP-1) receptor agonist during 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bydureon (Type: EXPERIMENTAL): Once weekly injected exenatide
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with 5 to 20 clinically typical, visible and discrete, actinic keratosis (AKs) non-hyperkeratotic and non-hypertrophic AKs within a selected treatment area of sun-damaged skin on either:~* The full face~* The full balding scalp~* A contiguous area of approximately 250 cm2 on the chest~Exclusion Criteria:~* Location of the treatment area (full face, full balding scalp or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).~* Previously assigned treatment in this clinical trial or previously participated in a clinical trial in the LEO clinical programme on ingenol mebutate gel for larger treatment areas.~* Treatment with ingenol mebutate gel in the selected treatment area within the last 12 months.~* Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous horn) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ingenol mebutate gel (Type: EXPERIMENTAL): Treatment once daily for 3 days
- Vehicle (Type: PLACEBO_COMPARATOR): Treatment once daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with inadequate response to statins or statin intolerance as defined below \[Inadequate response to statins\] Patients with hyper-LDL cholesterolemia who have been taking statins\[and other lipid-modifying therapies(LMTs) if needed\] and cannot achieve the lipid management goals of LDL-C \[Statin intolerance\] Patients with hyper-LDL cholesterolemia for whom safety problems have occurred while taking at least one type of statin, and who experienced resolution of the problems after discontinuation or dose reduction, and who cannot achieve the lipid management goals of LDL-C. Patients must be on the lowest or under the dosage of the approved dose of statin and/or on stable LMT(s).~* Patients with fasting TG levels of \<400 mg/dL at screening~* Other protocol specific inclusion criteria may apply~Exclusion Criteria:~* Females who are pregnant or breast-feeding or who have a positive pregnancy test (urine) result at screening or baseline visits~* Patients with homozygous familial hypercholesterolemia (HoFH)~* Patients who currently have or who have had within the past 3 months prior to screening any cardiovascular diseases, or those who have developed any cardiovascular diseases during the screening or before baseline visit~* Uncontrolled hypertension, defined as sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening~* Patients with uncontrolled and serious hematologic or coagulation disorders or with hemoglobin of \<10.0 g/dL at screening~* Patients with uncontrolled diabetes with HbA1c of ≥9% at screening~* Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of \>1.5 × ULN at screening~* Patients with liver disease or dysfunction, including:~  * Positive serology for hepatitis B surface antigen (HBsAg) or a positive hepatitis C virus (HCV) antibody test at screening~ * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN or total bilirubin of ≥2 × ULN at screening~* Patients with creatine kinase (CK) of \>3 × ULN at screening~* Patients with a history or current renal dysfunction, nephritic syndrome, or nephritis, and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73 m2 at screening~* Other protocol specific exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 180mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnoses of cIAI.~* Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous draining of an abscess) within 24 hours of (before or after) the first dose of study drug.~Exclusion Criteria:~* Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis; pancreatic abscess; or pelvic infections.~* Complicated intraabdominal infection managed by staged abdominal repair (STAR), open abdomen technique including temporary closure of the abdomen, or any situation where infection source control is not likely to be achieved.~* Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first dose of study drug, unless there is a documented treatment failure with such therapy.~* Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity \[e.g., daptomycin, vancomycin, linezolid\] are allowed).~* Severe impairment of renal function (estimated CrCl \< 30 mL/min), or requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (\< 20 mL/h urine output over 24 hours).~* The presence of hepatic disease at baseline.~* Considered unlikely to survive the 4 to 5 week study period.~* Any rapidly-progressing disease or immediately life-threatening illness (including respiratory failure and septic shock).~* Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibacterial (a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment), including cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole, or nitroimidazole derivatives.~* Women who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CXA-201 and Metronidazole as treatment for cIAI (Type: EXPERIMENTAL): None
- Meropenem as treatment for cIAI (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* borderline blood pressure (120-145/80-90 mm Hg);~* borderline or abnormal small artery elasticity (C2) as measured by pulse contour analysis;~* treatment-naive for all blood pressure medications including diuretics for at least 30 days prior to baseline visit;~* able to walk on a treadmill for 3 minutes;~* female patients with reproductive potential must use an approved contraceptive method if appropriate (for example, intrauterine device \[IUD\], birth control pills, or barrier device during and for 1 month after the last dose of study drug;~* voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~Exclusion Criteria:~* history of intolerance to beta-blockers or clear contraindications to their use; current pharmaceutical treatment of blood pressure;~* known history of cardiovascular disease (myocardial infarction, coronary artery bypass graft, unstable angina, uncontrolled arrhythmias, stroke, etc.);~* known history of diabetes; known history of hepatic, renal or gastrointestinal disorder;~* known history of any illness that may cause additional risk (as determined by study investigator);~* pregnant or lactating women \[when used during pregnancy, beta-blockers may cause fetal harm\];~* participation in a concomitant clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): 5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
- Atenolol (Type: ACTIVE_COMPARATOR): 25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
- Placebo (Type: PLACEBO_COMPARATOR): Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete